酒精使用障碍(AUD)是一种与营养不良相关的慢性复发性疾病,代谢紊乱,以及与心理症状严重程度相关的肠道微生物群改变。本研究旨在在戒酒期间补充AUD患者的益生元纤维,为了调节肠道菌群组成并评估其对胃肠道耐受性的影响,新陈代谢,和病人的行为。一个随机的,双盲,安慰剂对照研究包括50名AUD患者,他们每天服用菊粉和麦芽糖糊精,共17天.生物测量(粪便微生物16SrDNA测序,血清生物学),饮食摄入量,经过验证的心理问卷,在干预前后进行胃肠道耐受性评估。菊粉显着降低了包括双歧杆菌和拟杆菌在内的8个属(q<0.1)的丰富度和均匀度,并引起了变化。与安慰剂相比,益生元对胃肠道症状和营养摄入的影响较小。所有患者的抑郁症都有改善,焦虑,和戒酒期间的渴望得分,而与干预组无关。有趣的是,只有接受菊粉治疗的患者,其社交能力评分显著改善,血清脑源性神经营养因子水平升高.这项初步研究表明,菊粉具有良好的耐受性,可调节AUD患者的肠道微生物群和社会行为,与安慰剂相比,没有进一步改善其他心理和生物学参数。Gut2Brain研究,clinicaltrial.gov:NCT03803709,https://clinicaltrials.gov/ct2/show/NCT03803709.
Alcohol use disorder (AUD) is a chronic relapsing disease associated with malnutrition, metabolic disturbances, and gut microbiota alterations that are correlated with the severity of psychological symptoms. This
study aims at supplementing AUD patients with prebiotic fiber during alcohol withdrawal, in order to modulate the gut microbiota composition and to evaluate its effect on gastrointestinal tolerance, metabolism, and patient\'s behavior. A randomized, double-blind, placebo-controlled
study included 50 AUD patients assigned to inulin versus maltodextrin daily supplementation for 17 days. Biological measurements (fecal microbial 16S rDNA sequencing, serum biology), dietary intake, validated psychological questionnaires, and gastrointestinal tolerance assessment were performed before and after the intervention. Inulin significantly decreased the richness and evenness and induced changes of 8 genera (q < 0.1) including Bifidobacterium and Bacteroides. Prebiotic had minor effects on gastrointestinal symptoms and nutritional intakes compared to placebo. All patients showed an improvement in depression, anxiety, and craving scores during alcohol withdrawal regardless of the intervention group. Interestingly, only patients treated with inulin significantly improved the
sociability score and had an increased serum level of brain-derived neurotrophic factor. This pilot
study shows that inulin is well tolerated and modulates the gut microbiota and the social behavior in AUD patients, without further improving other psychological and biological parameters as compared to placebo. Gut2Brain
study, clinicaltrial.gov: NCT03803709, https://clinicaltrials.gov/ct2/show/NCT03803709.